CytomX Therapeutics Receives $20,000,000 Series C Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=a9a08b9f-defc-4822-b86a-76b90486f163 - Date
1/6/2015 - Company Name
CytomX Therapeutics - Mailing Address
343 Oyster Point Blvd. South San Francisco, CA 94080 USA - Company Description
CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodies, proteolytically-activated antibodies. - Website
http://www.cytomx.com - Transaction Type
Venture Equity - Transaction Amount
$20,000,000 - Transaction Round
Series C - Proceeds Purposes
The proceeds from this financing will help enable CytomX to advance our proprietary pipeline of Probody Drug Conjugates and Probodies against cancer immunotherapy checkpoint targets towards the clinic, while we also pursue Probody applications with bispecific antibodies and engineered T-cell therapies. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
